<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576130</url>
  </required_header>
  <id_info>
    <org_study_id>H-20007332</org_study_id>
    <nct_id>NCT04576130</nct_id>
  </id_info>
  <brief_title>A Danish ICD-study in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation</brief_title>
  <acronym>DanICD</acronym>
  <official_title>A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation Who Receive Complete Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit&#xD;
      of ICD-implantation in patients with coronary artery disease (including acute myocardial&#xD;
      infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular&#xD;
      tachycardia and undergo revascularization and with an LVEF above 35%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Anticipated">October 2032</completion_date>
  <primary_completion_date type="Anticipated">October 2032</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel-group, open-label, superiority trial with two arms with 1:1 randomization through an internet-based randomization module.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Treatment cannot be blinded, we will use several endpoints that do not require an endpoint committee evaluation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <description>The clinical event committee will aim to attribute the cause of death to the underlying disease process rather than the immediate mechanism. Mortality will be classified as cardiovascular and non-cardiovascular.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden cardiovascular death</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular death fulfilling the following criteria:&#xD;
In witnessed cases a change in cardiovascular status with time until death being &lt;1 hour.&#xD;
In unwitnessed cases &lt;24 hours since last seen alive and functioning normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality is considered as cardiovascular unless it is clearly attributable to another cause and thus includes:&#xD;
Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure).&#xD;
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.&#xD;
All procedure-related deaths, including those related to a complication of the ICD-procedure or treatment for a complication of the procedure.&#xD;
All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events.&#xD;
Death of unknown or cardiac cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device revision or replacement due to infection or malfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Explorative outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Appropriate shock from an ICD (successfully treated VT/VF)</measure>
    <time_frame>1 year</time_frame>
    <description>Explorative outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Inappropriate shock from an ICD (shock on non-VT/VF)</measure>
    <time_frame>1 year</time_frame>
    <description>Explorative outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Register-based all cause mortality</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Register-based sudden cardiovascular death</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Register-based sudden cardiovascular death</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Register-based cardiovascular death</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Register-based cardiovascular death</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Ventricular Fibrillation</condition>
  <condition>Ventricular Tachycardia, Sustained</condition>
  <condition>Out-Of-Hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>ICD-implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an ICD either during admission or within 4 weeks after discharge from index event.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Guideline directed medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable cardioverter defibrillator</intervention_name>
    <description>Implantation of an ICD for secondary prevention</description>
    <arm_group_label>ICD-implantation</arm_group_label>
    <other_name>ICD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with&#xD;
             complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD&#xD;
             implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic&#xD;
             total occlusion) or high-risk invasive treatment is not mandatory in order to achive&#xD;
             complete revascularization.&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  LVEF &gt;35% at the time of discharge. The most recent LVEF assessment on which the&#xD;
             current medical treatment will be based at the time of entry into the study will be&#xD;
             used as baseline LVEF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic&#xD;
             cardiomyopathy)&#xD;
&#xD;
          -  Previous CABG within the last 3 months before index hospitalization&#xD;
&#xD;
          -  Life expectancy less than 1 year or severe neurologic outcome&#xD;
&#xD;
          -  Unable or unwilling to give informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Jabbari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reza Jabbari, MD, PhD</last_name>
    <phone>+4535455380</phone>
    <email>reza.jabbari.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Engstrøm, MD, PhD, DMSc</last_name>
    <phone>+4535458444</phone>
    <email>thomas.engstroem@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Jabbari, MD, PhD</last_name>
      <phone>+4535455380</phone>
      <email>reza.jabbari.02@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Reza Jabbari</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Revascularization</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

